The gene encoding the human muscarinic receptor, type 1 (CHRM1), was genotyped from 245 samples of the Coriell Collection (Coriell Institute for Medical Research, Camden, NJ). Fifteen single nucleotide polymorphisms (SNPs) were discovered, 9 of which are located in the coding region of the receptor. Of these, 8 represent synonymous SNPs, indicating that CHRM1 is highly conserved in humans. Only a single allele was found to contain a nonsynonymous SNP, which encodes an amino acid change of Cys to Arg at position 417. This may have functional consequences because a C417S point mutation in rat M1 was previously shown to affect receptor binding and coupling. Furthermore, 0 of 4 SNPs within CHRM1 previously deduced from sequencing of the human genome were found in this study despite a prediction that a majority of such inferred SNPs are accurate. The consensus sequence of CHRM1 obtained in our study differs from the deposited reference sequence (AC NM_000738) in 2 adjacent nucleotides, leading to a V173M change, suggesting a sequencing error in the reference sequence. The extraordinary sequence conservation of the CHRM1 gene-coding region was unexpected as M1-knockout mice show only minimal functional impairments.
pharmacogenetics muscarinic acetylcholine receptor single nucleotide polymorphism G protein coupled receptor CHRM1
This is a preview of subscription content, log in to check access.
Levey AI, Kitt C, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor in proteins in brain with subtype-specific antibodies. J Neurosci. 1991;11(10):3218–3226.PubMedGoogle Scholar
Hamilton SE, Schlador ML, McKinnon LA, Chmelar RS, Nathansom NM. Molecular mechanisms for the regulation of the expression and function of muscarinic acetylcholine receptors. J Physiol (Paris). 1998;92:275–278.CrossRefGoogle Scholar
Hamilton S, Hardouin SN, Anagnostaras SG, et al. Alteration of cardiovascular and neuronal function in ml knockout mice. Life Sci. 2001;68:2489–2493.PubMedCrossRefGoogle Scholar
Bartus RT. On neurodegenerative diseases, models and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol. 2000;163:495–529.PubMedCrossRefGoogle Scholar
Fisher A, Brandeis R, Haring R, et al. Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: an unifying hypothesis. J Physiol (Paris). 1998;92:337–340.CrossRefGoogle Scholar
Fisher A, Michealson DM, Brandeis R, Haring R, Chapman S, Pittel Z. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease: Rationale and perspectives. Ann N Y Acad Sci. 2000;920:315–320.PubMedCrossRefGoogle Scholar
Sadee W, Hoeg E, Lucas J, Wang D. Genetic variation in human G protein coupled receptors: Implications for drug therapy. AAPS PharmSci. 2001;3(3); Article 22. Available from: http://www.pharmsci.org/scientificjournals/pharmsci/journal/01_22.htmlGoogle Scholar
Wang D, Quillan JM, Winans K, Lucas JL, Sadee W. Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem. 2001;276(37):34624–34630.PubMedCrossRefGoogle Scholar
Fallin D, Cohen A, Essioux L, et al. Genetic analysis of case/control data using estimated haplotype frequencies: Application to APOE locus variation and Alzheimer's disease. Genome Res. 2001;11:143–151.PubMedCentralPubMedCrossRefGoogle Scholar
Klett C, Bonner TI. Identification and characterization of the rat m1 muscarinic receptor promoter. J Neurochem. 1999;72(3):900–909.PubMedCrossRefGoogle Scholar
Savarese T, Wang CD, Fraser CM. Site directed mutagenesis of the rat m1 muscarinic acetylcholine receptor: Role of conserved cysteines in receptor function. J Biol Chem. 1992;267(16):11439–11448.PubMedGoogle Scholar